- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EGA Calls for Removal of Barriers to Generics in Europe
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Speaking at the 5th Bruges European Business Conference, van den Hoven maintained that the move would be in the interest of creating a pro-competitive pharmaceutical market in the EU and fostering sustainable competition.
He underlined the crucial role for Europe as a strong EU pharmaceutical export base, to be achieved through regulatory convergence with key trade partners and regulatory approximation in the EU with developing and emerging countries.
The Bruges conference was hosted by the College of Europe and included representatives from the European institutions, national governments and academia, and business leaders from all industrial sectors. Speakers included Dr. Wolfgang Schauble, German Minister of Finance and Prof. Mario Monti, former European Commissioner and Italian Prime Minister.
This entry was posted in
Europe
,
Events
,
Global
,
Regulatory
and tagged
Bruges European Business Conference
,
EGA
,
EU
,
European Generics Association
,
generics
. Bookmark the
permalink
. Trackbacks are closed, but you can
post a comment
.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
